Core Insights - Medtronic plc reported a strong Q2 FY26 with revenue of $9.0 billion, reflecting a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [1] - The company raised its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66 [1] - Cardiac Ablation Solutions experienced significant growth of 71%, with a remarkable 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio [1] Financial Performance - GAAP diluted EPS increased by 8% to $1.07, while non-GAAP diluted EPS also rose by 8% to $1.36, both above guidance [1] - The cardiovascular segment achieved its strongest revenue growth in over a decade, excluding pandemic effects [1] Product Developments - The company received broad favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity™ procedure, targeting an addressable market of 18 million people with uncontrolled hypertension [1] - Medtronic secured U.S. FDA approval for the Altaviva™ device, aimed at treating urge urinary incontinence, which affects over 16 million people in the U.S. [1] - The Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints in the Enable Hernia Repair study and initiated the Embrace Gynecology US pivotal study [1] - The U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes [1]

Core Insights - Medtronic has received FDA approval for the Altaviva device, a minimally invasive implantable tibial neuromodulation therapy aimed at treating urge urinary incontinence, which affects approximately 16 million people in the U.S. [1][2][3] - The Altaviva device is designed to improve bladder control by sending electrical impulses to the tibial nerve, and it features a 15-year battery lifespan with automatic therapy delivery [2][3]. Company Overview - Medtronic is a global leader in healthcare technology, with a mission to alleviate pain, restore health, and extend life, employing over 95,000 people across more than 150 countries [5]. - The company has a comprehensive portfolio of neuromodulation therapies for bladder control, positioning itself as the only company with such a full offering in this area [3]. Product Details - The Altaviva device is approximately half the length of a stick of chewing gum and is implanted near the ankle without the need for sedation or imaging [2]. - The device is MRI-compatible and designed for real-life needs, allowing patients to return home with therapy activated immediately after the procedure [2][3]. Market Impact - The introduction of the Altaviva device is expected to transform the treatment landscape for urge urinary incontinence, providing new hope and improved quality of life for patients [2][3]. - Medtronic plans to host an investor call to discuss the Altaviva device and its implications for the treatment of urge urinary incontinence on October 9, 2025 [3].